Antisense oligonucleotide (apoC-III)
Volanesorsen
Brand names: Waylivra
Adult dose
Dose: 285mg SC weekly initially; reduce to fortnightly per platelet response
Route: SC
Frequency: weekly/fortnightly
Clinical pearls
- Familial chylomicronaemia syndrome at risk of pancreatitis
- Per NICE TA784; weekly platelet monitoring
Contraindications
- Severe thrombocytopenia
- Pregnancy
- Severe hepatic/renal impairment
- Hypersensitivity
Side effects
- Severe thrombocytopenia (boxed)
- Bleeding
- Injection-site reactions
- Hepatic transaminitis
- Renal impairment
Interactions
- Antiplatelets
- Anticoagulants
- NSAIDs
Monitoring
- Platelets (weekly)
- LFTs
- Triglycerides
Reference: BNF; NICE TA784; SmPC; https://bnf.nice.org.uk/drugs/volanesorsen/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016